Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

JERUSALEM, Jan. 6, 2025 /PRNewswire/ — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices unit, announced today that its CEO, Mr. Amir Reichman, and Chairman of the Board, Mr. Mark Germain, will attend the IATI Mini Mixiii Conference in Miami, FL on Jan 9, 2025 and the JP Morgan HealthCare Conference week in San Francisco from Jan 13-15, 2025. On Jan 14, 2025, Mr. Reichman and Mr. Germain will also participate in the SIC Biotech Symposium in San Francisco.